Fernando Martín Moro, Internal Med student at Hematología Salamanca, shared on X:
“New drugs in DLBCL frontline.
ASH24 thread:
Zilovertamab Vedotin (ROR1 inhibitor) + R-CHP [Waveline-007 trial]
Good safety profile and CR rate almost 100%!
Golcadomide (CELMoD) + R-CHOP
– High rates of durable CMRs without regarding COO.
– 0.4 mg doses appears to overcome molecular high risk patients.
– Neutropenia as most relevant AE.
– Phase 3 trial ongoing.
Parsaclisib (PI3K inhibitor) + R-CHOP/Pola-R-CHP in high-risk LBCL (non-GCB, MYC+ >40%, BCL2+ >50%, DE or MYC rearrangement).
Parsaclisib + R-CHOP -> ORR 98%/CR 91%.
Parsaclisib + Pola-R-CHP -> ORR and CR 100%.
AEs as spected!
Epcoritamab (CD3xCD20 BiTE)+ R-CHOP [EPCORE NHL-2]
– Responses irrespective of high-risk characteristics
– Prompt remission with uMRD (after C2)
– DH/TH as good as DLBCL
– CRS 60% (most C1 D15), ICANS 4%
Glofitamab (CD3xCD20 BiTE) and R-CHOP/Pola-R-CHP.
High CR rates: 98% (ORR 100%). BUT the addition of Pola does not improve outcome , while is related with higher rates of AEs.”
